Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2014

01.05.2014 | case report

Activity of nab-paclitaxel in a heavily-pretreated breast cancer patient who experienced a change of tumour biology

verfasst von: Ursula Pluschnig, MD, Hans-Jörg Neumann, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The patient described here was diagnosed with hormone-receptor-positive breast cancer and underwent numerous treatments in the neoadjuvant, adjuvant and palliative settings. Metastatic disease occurred that was confined to the bone, but kept progressing over several years. Due to the short-lasting nature of the patient’s responses to various endocrine agents, a re-biopsy was performed and a hormone receptor switch to triple negativity was established. With nab-paclitaxel therapy, disease stabilisation has been achieved for 8 months. The patient has tolerated this therapy very well in spite of massive pretreatment.
Literatur
1.
Zurück zum Zitat Hoefnagel LD, van der Groep P, van de Vijver MJ, et al. Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Ann Oncol. 2013;24:3017–23.PubMedCrossRef Hoefnagel LD, van der Groep P, van de Vijver MJ, et al. Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. Ann Oncol. 2013;24:3017–23.PubMedCrossRef
2.
Zurück zum Zitat Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–8.PubMedCrossRef Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–8.PubMedCrossRef
3.
Zurück zum Zitat Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions. 1977;7:63–7.PubMedCrossRef Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions. 1977;7:63–7.PubMedCrossRef
4.
Zurück zum Zitat Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol. 1990;8:1263–8.PubMed Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol. 1990;8:1263–8.PubMed
5.
Zurück zum Zitat ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665–85.PubMedCrossRef ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665–85.PubMedCrossRef
6.
Zurück zum Zitat Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454–7.PubMed Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454–7.PubMed
7.
Zurück zum Zitat Winer E, Berry D, Duggan D, et al. Failure of higher-dose paclitaxel to improve outcome of patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004;22:2061–8.PubMedCrossRef Winer E, Berry D, Duggan D, et al. Failure of higher-dose paclitaxel to improve outcome of patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004;22:2061–8.PubMedCrossRef
8.
Zurück zum Zitat van Tellingen O, Huizing MT, Panday VR, et al. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999;81:330–5.PubMedCentralPubMedCrossRef van Tellingen O, Huizing MT, Panday VR, et al. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999;81:330–5.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.PubMedCrossRef Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.PubMedCrossRef
11.
Zurück zum Zitat Pusztai L, Viale G, Kelly CM, et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist. 2010;15(11):1164–8.PubMedCentralPubMedCrossRef Pusztai L, Viale G, Kelly CM, et al. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist. 2010;15(11):1164–8.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Curtit E, Nerich V, Mansi L, et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist. 2013;18:667–74.PubMedCentralPubMedCrossRef Curtit E, Nerich V, Mansi L, et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist. 2013;18:667–74.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Chen S, Chen CM, Yu KD, et al. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012;19(9):3002–11.PubMedCrossRef Chen S, Chen CM, Yu KD, et al. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012;19(9):3002–11.PubMedCrossRef
14.
Zurück zum Zitat Thompson AM, Jordan LB, Quinlan P, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010;12(6):R92.PubMedCentralPubMedCrossRef Thompson AM, Jordan LB, Quinlan P, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010;12(6):R92.PubMedCentralPubMedCrossRef
Metadaten
Titel
Activity of nab-paclitaxel in a heavily-pretreated breast cancer patient who experienced a change of tumour biology
verfasst von
Ursula Pluschnig, MD
Hans-Jörg Neumann, MD
Publikationsdatum
01.05.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0147-7

Weitere Artikel der Ausgabe 2/2014

memo - Magazine of European Medical Oncology 2/2014 Zur Ausgabe